37 results about "Chimeric gene" patented technology

To provide a medicine for treating a disease in a mammal.SOLUTION: Provided is a medicine for treating a disease in a mammal, comprising an expression cassette that is a first expression cassette comprising a chimeric gene operably linked to a first expression control element, the chimeric gene comprising a first portion comprising a minigene having an alternatively spliced exon and a second portion encoding a first RNA encoding a protein, the first portion being 5' to the second portion, the second portion lacking an initiation codon or start codon, the alternatively spliced exon comprising a translation initiation regulatory sequence, expression of the protein being controlled by inclusion of the alternatively spliced exon, and the medicine being used in combination with a small molecule splicing modifier that modulates splicing of the alternatively spliced exon.SELECTED DRAWING: Figure 1

The invention provides an establishment method of a transgenic mouse, and the method comprises the following steps: a transgenic mouse MHC chimeric gene is introduced into an endogenous B2m gene locus of the mouse, the MHC chimeric gene comprises a human B2M gene and a chimeric alpha-chain gene, and the chimeric alpha-chain gene comprises a human alpha1 region, a human alpha2 region and a mouse alpha3 region; the chimeric alpha-chain gene further comprises a mouse transmembrane region and a mouse intracellular region. The transgenic mouse disclosed by the invention can be applied to tumor specific antibody detection, in-vivo evaluation of vaccines, and in-vivo screening of TCR-T and other drugs.

The invention discloses a method for improving the inductivity and genetic transformation efficiency of hairy roots of toona ciliata. According to the method, agrobacterium rhizogenes carrying RUBY-TcGRF8-GIF2 chimeric protein are injected into stems and petioles of aseptic seedlings of the toona ciliata, and the TcGRF8-GIF2 chimeric gene is over-expressed, so that the induction efficiency and the genetic transformation efficiency of the toona ciliata hairy roots are remarkably improved, and the transformation period of the toona ciliata hairy roots is remarkably shortened. Specifically, after overexpression of the TcGRF8-GIF2 gene, the induction time of the hairy roots is shortened from 70 days of a RUBY-XbaI no-load plasmid control group to 25 days, the induction rate and conversion rate of the hairy roots mediated by agrobacterium tumefaciens are improved, the operation efficiency of genetic transformation of the toona ciliata is effectively improved, and the method has important significance for promoting genetic improvement of the toona ciliata.

The invention discloses a chimeric gene engineering nano vesicle for removing pathogenic antibodies as well as a preparation method and application of the chimeric gene engineering nano vesicle, and belongs to the technical field of biology. According to the invention, a stable transfection cell line of a protein A / G gene is constructed through lentiviral particle transfection, so that the protein A and the protein G can be stably expressed. The fusion protein A / G can overcome the defect of weak binding capacity of pure protein A and IgG3, and the adsorption effect of the antibody IgG is improved. The PLGA nanoparticles with relatively uniform particle size are adopted as the core of the target vesicle and are mixed with the engineered cell membrane broken by extrusion to promote self-assembly of the cell membrane and form an extracellular vesicle simulant, so that the stability of the target nano vesicle is improved. The prepared and separated nano vesicles can be applied to in-vivo adsorption and antibody removal, the biological safety is good, and the dialysis indwelling catheter operation risk in the use process of an existing immunoadsorption column and the risks of bleeding, allergy and the like in the treatment process are avoided.

The present invention relates to an isolated nucleic acid comprising a nucleotide sequence encoding a mutated HPPD protein, wherein said mutated HPPD protein has HPPD activity, wherein in said mutated HPPD protein at least one amino acid has been replaced so that the resulting amino acid sequence comprises at least one amino acid selected from certain amino acids at specific positions important for conferring an increased HPPD inhibitor tolerance. The present invention also relates to proteins encoded by the nucleic acid of the invention, to chimeric genes, plant cells comprising the nucleic acid of the invention operably linked to a plant-expressible promoter and optionally a transcription termination and polyadenylation region, plants essentially consisting of the plant cells of the invention and methods of obtaining transgenic plants.

The invention discloses a recombinant virus vector, a vesicular stomatitis-yellow rice chimeric virus and application of the vesicular stomatitis-yellow rice chimeric virus. The recombinant virus vector is a recombinant vector containing an expression cassette of a vesicular stomatitis-yellow rice chimeric genome; the expression cassette comprises a T7 promoter, a coding sequence of a vesicular stomatitis virus N protein, a coding sequence of a vesicular stomatitis virus P protein, a coding sequence of a vesicular stomatitis virus M protein, a coding sequence of a yellow virus F protein and a coding sequence of a vesicular stomatitis virus L protein which are connected in sequence. The replication-deficient recombinant virus for chimeric expression of the LayV F protein is constructed on the basis of the VSV vector, the safety is good, the immunogenicity is good, a high-titer specific IgG antibody and a neutralizing antibody aiming at LayV can be induced to be generated through intramuscular or subcutaneous injection, a new technical choice is provided for preventing or blocking LayV infection, and the replication-deficient recombinant virus has important use and popularization values.

The present disclosure provides methods for inducing callus formation and plant regeneration from isolated protoplasts of grape. This technology allows for the production of non-chimeric gene edits in grape plants by allowing the delivery of DNA through the plant cell membrane with the recovery of whole plants from a single edited cell.

Provided is an Alzheimer's disease rat model or a tissue or cell thereof, which comprises a chimeric APP gene encoding a modified APP and use thereof.

The current invention provides an improved process of the manufacture of pharmaceutical products comprising proteins, useful for the prevention or treatment of leishmaniasis. The pharmaceutical composition comprises a protein chimera Q, which is the product of a chimeric gene encoding the antigenic determinants of four proteins of Leishmania infantum.

The present invention discloses a dominant B cell antigen epitope of the receptor binding domain (RBD) of the PEDV spike (S) protein, a chimeric gene thereof, a recombinant strain and a preparation method thereof, and an application thereof in a multi-linked and multivalent vaccine of ETEC and PEDV. The F4-F18-PEDV-S recombinant vaccine strain prepared by the present invention can simultaneously express the F4 and F18 pili of the porcine ETEC, as well as the dominant neutralizing B cell antigen epitope of the RBD of the PEDV S protein. The pili of the extracted recombinant vaccine strain are emulsified with Freund's adjuvant to immunize mice, and high levels of anti-FaeG, anti-FedF and anti-PEDV S protein antibodies can be simultaneously induced in the mice, and the serum of the immune mice can inhibit the adhesion of the F4+ ETEC and F18+ ETEC standard strains to the small intestinal cells of piglets in vitro; the neutralization titer to the PEDV2b strain (HSW) reaches 1:80. The recombinant vaccine strain is expected to be developed into a multi-linked and multivalent vaccine for preventing diarrhea in piglets caused by mixed infection of ETEC and PEDV, and has great application value.

The present invention relates to a chimeric protein consisting of a specific region of a protein selected from the group consisting of LIC 10123, LIC 13059, LIC 13050, LIC 12615, LIC 11636, LIC 11352, LIC 11122, LIC 11089, LIC 10713 and LIC 13434, which is demonstrated to be conservative and present on the surface of LIC 10123, LIC 13059, LIC 13050, LIC 12615, LIC 11636, LIC 11352, LIC 11122, LIC 11089, LIC 10713 and LIC 13434, wherein the specific region consists of the amino acid sequence defined by SEQ ID NO: 2, 4, 6, 7, 9, 11, 13, 14, 16, 18, 20 and 22 The invention further relates to a host microbial cell comprising a chimeric gene consisting of the nucleotide sequence shown in SEQ ID NO: 25, said chimeric gene and an expression cassette. In addition, the invention relates to a method for obtaining said chimeric protein and a leptospirosis serological diagnostic kit comprising the chimeric protein of the invention. Furthermore, the present invention relates to an in vitro method for the early serological diagnosis of leptospirosis and the use of said chimeric protein for the early serological diagnosis of leptospirosis by detecting IgM and / or IgG antibodies in a serum sample from a patient suspected of having leptospirosis.

The current invention provides an improved manufacturing process, in particular improved downstream processing, of pharmaceutical products especially comprising proteins, useful for the prevention or treatment of leishmaniosis. The pharmaceutical composition may comprise a protein chimera Q, which is the product of a chimeric gene encoding the antigenic determinants of four proteins of Leishmania infantum.

The invention relates to a tobacco CMS-S type cytoplasmic male sterility gene orf291 and application thereof in tobacco breeding, which are characterized in that the tobacco CMS-S type cytoplasmic male sterility gene orf291 is obtained by sequencing mitochondrial genomes of a tobacco sterile plant MSK326 and a fertile plant K326, and screening conditions that a candidate sterile gene sequence length exists, a transmembrane structure domain and a chimeric gene exist in the mitochondrial genomes of the sterile plant but do not exist in the mitochondrial genomes of the sterile plant, and the like. Finally, it is clear that the tobacco CMS-S type sterile gene orf291 is the only tobacco sterile gene meeting the same conditions, and a gene expression analysis result shows that orf291 is massively expressed in a tobacco sterile plant MSK326 and is not expressed in a fertile plant K326. The clear sequence of the CMS-S type sterile gene orf291 provides a necessary targeting target for subsequently creating a tobacco restorer line through targeted knockout of the gene and preventing and treating tobacco mitochondrial diseases, and has important application potential in tobacco crossbreeding.

The present invention discloses a high-expression nicotine chimeric gene, an expression vector and an application thereof, aiming to solve the technical problem of low nicotine biosynthesis efficiency in current tobacco. PMT1 The promoter contains the G-box element sequence "ATGCACGTTGTAAT", which realizes the regulation of the tobacco nicotine biosynthesis gene PMT, and the relevant chimeric genes and engineered bacteria are modified and designed. When applied to tobacco transformation, they can significantly increase the biosynthesis of tobacco nicotine.

The invention belongs to the technical field of molecular biology and genetic inspection, and discloses a primer group for rapidly detecting a 11beta-OHD pathogenic chimeric gene, the primer group comprises a CYP11B2-Intron 5-F primer, a CYP11B2-Intron 5-R primer, a CYP11B1-Intron 5-F primer and a CYP11B1-Intron 5-R primer, and the CYP11B1-Intron 5-R primer comprises a CYP11B2-Intron 5-F primer, a CYP11B1-Intron 5-R primer and a CYP11B1-Intron 5-R primer, the invention also discloses an application of the primer group in preparation of a product for detecting 11beta-OHD. The primer designed by the invention can be directly used for qPCR (quantitative polymerase chain reaction) detection, can preliminarily judge whether a 11 beta-OHD patient carries the CYP11B2 / CYP11B1 chimeric gene or not, can directly screen out the 11 beta-OHD patient and a carrier carrying the CYP11B2 / CYP11B1 chimeric gene more quickly and more conveniently in combination with a long-fragment PCR detection method, and is low in cost and high in specificity. The clinical conditions of misdiagnosis, missed diagnosis or delayed diagnosis on the 11 beta-OHD can be greatly improved, and the method has important innovative significance on rapid molecular detection of the 11 beta-OHD clinically.

Disclosed herein relates to a chimeric gene editing system comprising a modified retron editing system for precise and efficient gene editing. Additionally, a chimeric gene editing system that comprises one or more components of a prime editing system (or a prime editor-like system) with one or more components of a retron editing system, is disclosed, providing an entirely new gene editing system with distinct properties, capabilities and advantages.

The present invention relates to a Yarrowia lipolytica CBS 8108 strain for producing lipids, comprising one or more chimeric gene constructs, for overexpression of ACC1, MCE2 and / or DGA1 chimeric genes. In a second aspect, the invention relates to a method for producing lipids using said Y. lipolytica strain. The invention further pertains to lipids obtainable by the method, a composition comprising said lipids, a composition comprising Y. lipolytica strain, and a food product obtainable therefrom.

The present invention relates to a recombinant oleaginous yeast cell having at least one CEX1 gene disruption, comprising chimeric gene constructs, each of said chimeric gene constructs comprising a yeast-expressible promoter and a 3' end region comprising transcription termination and polyadenylation signals functioning in a yeast cell, wherein said chimeric gene constructs allow for overexpression of DGA1, ACC1, MCE2, and ACL genes, said ACL gene being ACL1 and / or ACL2 gene. In a second aspect, the invention relates to a method for producing lipids using said transformed oleaginous yeast cell. The invention further pertains to lipids obtainable by the method, a composition comprising said lipids, a composition comprising transformed oleaginous yeast cell, and a food product obtainable therefrom.

Provided are a chimeric genetically-engineered nano vesicle used for removing pathogenic antibodies, a preparation method therefor, and the use thereof, belonging to the technical field of biology. By means of lentivirus particle transfection, a stably transfected cell line of a protein A / G gene is constructed, so as to stably express protein A and protein G. A fusion protein A / G can overcome the defect of poor IgG3 binding capacity of pure protein A, thereby improving the effect of antibody IgG adsorption. In addition, using PLGA nanoparticles having relatively uniform particle sizes as the core of the target vesicle and mixing same with engineered cell membranes that are ruptured by compression can promote self-assembly of cell membranes, so as to form extracellular vesicle mimetics, thereby improving the stability of the target nano vesicle. The prepared and separated nano vesicle can be applied to in-vivo adsorption and removal of antibodies, has good biological safety, and avoids the risk of dialysis catheterization operation during using processes and the risks such as bleeding and allergy during treatment processes of immunoadsorption columns.

The invention belongs to the technical field of biological medicines, and particularly relates to a porcine reproductive and respiratory syndrome nucleic acid vaccine adjuvant for activating Toll-like receptor3 as well as a preparation method and application of the porcine reproductive and respiratory syndrome nucleic acid vaccine adjuvant. The nucleic acid vaccine adjuvant for the porcine reproductive and respiratory syndrome contains a recombinant sequence which takes human serine tRNA as a bracket and is embedded with a conserved sequence of 3 'UTR in a PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) genome. The conserved sequence of the 3 'UTR in the chimeric PRRSV genome is a sequence with the similarity of more than 90% with SEQ ID NO.1, and the recombinant sequence of the 3' UTR in the chimeric PRRSV genome is a sequence with the similarity of more than 70% with SEQ ID NO.2. The nucleic acid vaccine adjuvant produced by the invention has low toxicity and low immunogenicity, and can activate TLR3 and induce high-level antibody and cellular immune response.

The application provides a construction method and application of a humanized hNOTCH3 gene animal model, the model expresses a human-animal chimeric NOTCH3 gene in vivo, and the chimeric NOTCH3 protein expressed includes a human NOTCH3 protein extracellular main functional domain, and can be used for NOTCH3 gene function research, screening and evaluation of human NOTCH3 targeted drugs and therapies. The animal model prepared by using the application can be used for quickly establishing more different hNOTCH3 gene humanized disease animal models of NOTCH3 gene mutations, drug screening for human NOTCH3 target sites, pharmacodynamic research, related nervous system diseases and tumor treatment and the like, accelerates a new drug research and development process, saves time and cost, and reduces drug development risks.

The present invention provides chimeric genes and constructs which can be used to alter the lignin composition of woody plants and increase the saccharification and pulping efficiency of said plants. Particularly the lignin composition is modified by the incorporation of scopoletin.